<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02391168</url>
  </required_header>
  <id_info>
    <org_study_id>FLD2015</org_study_id>
    <nct_id>NCT02391168</nct_id>
  </id_info>
  <brief_title>Fatty Liver Disease Collaborative Research in China</brief_title>
  <acronym>FLDCR</acronym>
  <official_title>A Multi-center, Prospective Cohort Study on the Natural History of Fatty Liver Disease in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fatty Liver and Alcoholic Liver Disease Study Group, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Unimed Scientific Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fatty Liver and Alcoholic Liver Disease Study Group, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, prospective cohort study on the natural history of fatty liver disease in
      China
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, prospective and open-enrollment epidemiologic study. All the patients
      with liver biopsy-proven macrovesicular steatosis (&gt;5%) will be enrolled in the baseline
      cross-sectional analysis. Those who are either diagnosed as NAFLD or ALD, if meeting all the
      inclusion and exclusion criteria, will be enrolled in the following cohort study, will be
      followed up after 1 year, 3 years and 5 years with a visit window of +1 month.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>liver cirrhosis</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>liver cancer</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver failure</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type 2 diabetes</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular and cerebrovascular events</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Fatty Liver</condition>
  <condition>Fatty Liver, Alcoholic</condition>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Liver tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        any person with fatty liver disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically diagnosed fatty liver disease, confirmed by liver biopsy.

          -  Specific biopsy requirements: qualified biopsy specimen within 6 months, &gt;5%
             hepatocytes show macrovesicular steatosis under HE staining and X10 microscope.

          -  Only patients with NAFLD or ALD are eligible for the 5-year follow-up cohort study.

          -  Willing to participate in the long-term follow-up and cooperative.

          -  Able to provide informed consent file.

        Exclusion Criteria:

          -  Unable to provide informed consent.

          -  Patients are eligible for baseline cross-sectional analysis but not eligible for the
             cohort section, if having any of the following condition:

               1. Any end-stage liver disease.

               2. Any malignant tumor.

               3. Any infection of hepatitis virus or HIV.

               4. Any congenital liver disease such as Wilson disease.

               5. Any other serious disease of projected survival &lt; 5 years.

               6. Combined NAFLD and ALD.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiangao Fan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiangao Fan, MD</last_name>
    <email>fattyliver2004@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chao Sun, MD</last_name>
    <email>csun7682@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhangzhou Zhengxing Hospital</name>
      <address>
        <city>Zhangzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruidan Zheng, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ruidan Zheng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Ji'nan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wanhua Ren, MD</last_name>
    </contact>
    <investigator>
      <last_name>Wanhua Ren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Second People's Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuqiang Mi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yuqiang Mi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fangping He, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fangping He, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Hangzhou Normal University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Junping Shi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Junping Shi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Xinhua Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiangao Fan, MD</last_name>
      <email>fattyliver2004@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2015</study_first_submitted>
  <study_first_submitted_qc>March 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <last_update_submitted>August 3, 2015</last_update_submitted>
  <last_update_submitted_qc>August 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Fatty Liver, Alcoholic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

